Navigation Links
Immtech Investor Conference Call Scheduled for February 22, 2008
Date:2/19/2008

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) will have an investor conference call on February 22, 2008, at 4.30PM (ET) to present an update on the Company. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is # 36251882. To register, please call no later than 10 minutes prior to the scheduled start of the call. A recording of the conference call will be available on the Company's website (http://www.immtechpharma.com) from February 23, 2008 to March 14, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. ("Immtech") is a pharmaceutical company working to commercialize drugs to treat infectious diseases and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit Immtech's website at http://www.immtechpharma.com.

This press release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Completes Malaria Prevention Trial
4. MDS to Provide Financial Guidance at 2008 Annual Investor Day
5. Investor Insight Initiates Analyst Coverage on Crdentia
6. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
7. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
8. MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc.
9. Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... According to the ... performed each year, putting it among the top 5 most popular minimally-invasive cosmetic procedures ... those million-plus procedures will be performed over the next 8-10 weeks. For anyone considering ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education for ... Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart ... to help nutrition educators and students inform consumers about the health benefits of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ... co-op eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, ... agricultural equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... ... Sports Brand EXOUS Bodygear announced today a special sale price for the ... days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... (regular retail price $19.97). , The special promotional prices are to help individuals get ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... Proton Therapy Market in Italy will double ... are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton beams ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
Breaking Medicine Technology: